Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers
Authors:
Open Access
- 26 June 2015
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 24 (2) , 621-627
Abstract
Purpose The use of serotonin type 3 (5-HT3) receptor antagonists (RAs) in the prevention of nausea and vomiting caused by emetogenic chemotherapy is part of a comprehensive management strategy for patients undergoing chemotherapy. Electrocardiographic effects have been reported in patients after intravenous administration of 5-HT3 RAs. The present study investigated the electrocardiogram (ECG) profile of the 5-HT3 RA palonosetron following International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E14 Guidelines. Methods A total of 221 healthy subjects (101 females, 120 males) were randomized in this phase I, double-blind, double-dummy, parallel group study and assigned to one of five treatments: placebo, palonosetron (0.25, 0.75, or 2.25 mg), or moxifloxacin (400 mg). ECGs were recorded for 24 h pre-dosing until 48 h post-dose. The primary endpoint was the placebo time-matched and baseline-subtracted individual QTc interval prolongation (ΔΔQTcI). Results The QTc interval was not prolonged after administration of palonosetron (ΔΔQTcI upper confidence interval was <10 ms for all time points in all palonosetron treatment groups). Assay sensitivity was confirmed with the expected change in the QTc interval after administration of the positive control moxifloxacin. Conclusions Palonosetron, even at supratherapeutic doses, has no effect on cardiac repolarization as measured by the QTc interval in a validated controlled clinical trial.Keywords
This publication has 31 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceAnnals of Oncology, 2010
- Prevention of Postoperative Nausea and VomitingAnnals of Pharmacotherapy, 2007
- Drugs that cause torsades de pointes and increase the risk of sudden cardiac deathCurrent Cardiology Reports, 2004
- Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug developmentJournal of Electrocardiology, 2004
- QT Prolongation and Fatal Arrhythmias: A Review of Clinical Implications and Effects of DrugsAmerican Journal of Therapeutics, 2003
- Survey Ranking of Emetogenic Control in Children Receiving ChemotherapyJournal of Pediatric Hematology/Oncology, 2000
- Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonistsBritish Journal of Cancer, 1997
- Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.Journal of Clinical Oncology, 1994
- Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimensBlood Reviews, 1989